The future of pharmacogenetics in the treatment of migraine
| Autor: | Paolo Martelletti, Martina Guglielmetti, Marina Borro, Maurizio Simmaco, Giovanna Gentile |
|---|---|
| Rok vydání: | 2019 |
| Předmět: |
0301 basic medicine
medicine.medical_specialty Drug-Related Side Effects and Adverse Reactions Migraine Disorders Pharmacological management Neurological disorder drug-genotype interactions Genetic profile 03 medical and health sciences 0302 clinical medicine Genetics medicine Humans migraine Drug Interactions Precision Medicine Intensive care medicine drug-drug interactions (DDIs) Pharmacology business.industry pharmacogenetics precision medicine Anti-Inflammatory Agents Non-Steroidal medicine.disease Precision medicine 030104 developmental biology Migraine Pharmacogenetics Concomitant Molecular Medicine business 030217 neurology & neurosurgery |
| Zdroj: | Pharmacogenomics. 20:1159-1173 |
| ISSN: | 1744-8042 1462-2416 |
| Popis: | Migraine is considered one of the most disabling neurological disorder with a high socioeconomic burden. Pharmacological management includes many classes of drugs which in the most cases, are administrated in polytherapy. The therapeutic scheme of migraineurs is often affected by comorbidities which need concomitant medications, thus increasing the risk of side effects related to drug-drug interactions. Pharmacogenetics is a promising tool to achieve a personalized cure based on individual genetic profile while the availability of free online knowledge bases allows to check the potential DDIs of selected medications. Combining, these approaches may offer to clinicians a useful tool to improve the appropriateness of migraine polytherapy choice, aiming to increase the efficacy and reduce the toxicity of pharmacological treatments. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|